FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387433013> ?p ?o ?g. }

• W4387433013 endingPage "80" @default.
• W4387433013 startingPage "76" @default.
• W4387433013 abstract "The study aimed to analyse the adverse drug reactions report form data received by the State Expert Center of the Ministry of Health of Ukraine from healthcare professionals in the Lviv region in 2022. Regarding specific types of medicines, the ones with proven cause-and-effect relationships that caused the highest frequency of adverse drug reactions incidents were chemotherapeutic agents (35.5%), medicines affecting the cardiovascular system (20.3%), and non-steroidal anti-inflammatory drugs (8%). Within the penicillin class, amoxicillin potentiated by clavulanate (67%) and amoxicillin (29%) were the dominant drugs showing the highest incidence rate of adverse reactions. Among cephalosporins, ceftriaxone (46%) and cefixime (15%) were found to take the lead in terms of adverse reaction frequency. The highest proportion among all adverse drug reactions caused by penicillins and cephalosporins was attributed to allergic reactions. To confirm or rule out immediate or delayed type allergies in patients, as well as in patients with a history of immediate-type allergic reactions to β-lactams and planned administration of another β-lactam, it is necessary to conduct skin testing (skin prick test, or, in the case of parenteral administration, intradermal test) with the planned β-lactam antibiotic. The second highest proportion of induced adverse drug reactions was attributed to drugs affecting the cardiovascular system (20.3%). The leading medications in the angiotensin-converting enzyme inhibitors category were enalapril (47%) and the combination of lisinopril with hydrochlorothiazide (24%). In the angiotensin II receptor blockers category of medications, valsartan (30%) and telmisartan-hydrochlorothiazide combination (20%) ranked highest. In the category of CCB drugs, amlodipine (66%) and nifedipine (20%) held the leading positions. among angiotensin-converting enzyme inhibitors, enalapril caused the most prevalent and predicted adverse reaction, that of cough, affecting 10.5% of patients, whereas, with the combination therapy of lisinopril and hydrochlorothiazide, the cough was observed in only 5.2% of patients. Angiotensin II receptor blockers have a better safety profile, particularly concerning cough. Analysis of adverse drug reactions reports for angiotensin II receptor blockers showed no cases of cough with valsartan and telmisartan-hydrochlorothiazide combination. Among calcium channel blocker medications, amlodipine emerged to rank highest, causing one of the predicted adverse drug reactions, that of lower extremity oedema in 64% of patients. The second position was taken by the combination of amlodipine with valsartan, which showed a statistically significant reduction of 14.3% (p≤0.05) in the incidence of oedema. Using amlodipine at a dose of 5 mg in combination with sartan medicines as angiotensin receptor blockers is an effective therapeutic alternative not only for enhancing blood pressure control in hypertensive patients but also for improving the safety profile of amlodipine. Among all the non-steroidal anti-inflammatory drugs prescribed to patients in the Lviv region in 2022, the highest number of adverse reactions was associated with the administration of diclofenac, ibuprofen, paracetamol, and nimesulide, causing adverse drug reactions in 22%, 19%, 17%, and 10% of cases, respectively. The most common systemic manifestations of adverse reactions with these non-steroidal anti-inflammatory drugs were allergic reactions (63.4%) and gastrointestinal disorders (26.8%). From an evidence-based medicine perspective, the most justified approach for primary and secondary prevention of gastrointestinal complications is the use of proton pump inhibitors." @default.
• W4387433013 created "2023-10-09" @default.
• W4387433013 creator A5016675486 @default.
• W4387433013 creator A5017954267 @default.
• W4387433013 creator A5033559828 @default.
• W4387433013 creator A5046528012 @default.
• W4387433013 creator A5072612864 @default.
• W4387433013 creator A5093023386 @default.
• W4387433013 date "2023-10-08" @default.
• W4387433013 modified "2023-10-09" @default.
• W4387433013 title "MANAGEMENT OF RISKS OF ADVERSE DRUG REACTIONS ACCORDING TO ADR REPORT FORM DATA FROM LVIV REGION HEALTHCARE FACILITIES IN 2022." @default.
• W4387433013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37805878" @default.
• W4387433013 hasPublicationYear "2023" @default.
• W4387433013 type Work @default.
• W4387433013 citedByCount "0" @default.
• W4387433013 crossrefType "journal-article" @default.
• W4387433013 hasAuthorship W4387433013A5016675486 @default.
• W4387433013 hasAuthorship W4387433013A5017954267 @default.
• W4387433013 hasAuthorship W4387433013A5033559828 @default.
• W4387433013 hasAuthorship W4387433013A5046528012 @default.
• W4387433013 hasAuthorship W4387433013A5072612864 @default.
• W4387433013 hasAuthorship W4387433013A5093023386 @default.
• W4387433013 hasConcept C126322002 @default.
• W4387433013 hasConcept C174802600 @default.
• W4387433013 hasConcept C177713679 @default.
• W4387433013 hasConcept C197934379 @default.
• W4387433013 hasConcept C27016395 @default.
• W4387433013 hasConcept C2777880890 @default.
• W4387433013 hasConcept C2779515644 @default.
• W4387433013 hasConcept C2779708577 @default.
• W4387433013 hasConcept C2780035454 @default.
• W4387433013 hasConcept C2780361556 @default.
• W4387433013 hasConcept C2780542314 @default.
• W4387433013 hasConcept C501593827 @default.
• W4387433013 hasConcept C64778159 @default.
• W4387433013 hasConcept C71924100 @default.
• W4387433013 hasConcept C84393581 @default.
• W4387433013 hasConcept C86803240 @default.
• W4387433013 hasConcept C89423630 @default.
• W4387433013 hasConcept C98274493 @default.
• W4387433013 hasConceptScore W4387433013C126322002 @default.
• W4387433013 hasConceptScore W4387433013C174802600 @default.
• W4387433013 hasConceptScore W4387433013C177713679 @default.
• W4387433013 hasConceptScore W4387433013C197934379 @default.
• W4387433013 hasConceptScore W4387433013C27016395 @default.
• W4387433013 hasConceptScore W4387433013C2777880890 @default.
• W4387433013 hasConceptScore W4387433013C2779515644 @default.
• W4387433013 hasConceptScore W4387433013C2779708577 @default.
• W4387433013 hasConceptScore W4387433013C2780035454 @default.
• W4387433013 hasConceptScore W4387433013C2780361556 @default.
• W4387433013 hasConceptScore W4387433013C2780542314 @default.
• W4387433013 hasConceptScore W4387433013C501593827 @default.
• W4387433013 hasConceptScore W4387433013C64778159 @default.
• W4387433013 hasConceptScore W4387433013C71924100 @default.
• W4387433013 hasConceptScore W4387433013C84393581 @default.
• W4387433013 hasConceptScore W4387433013C86803240 @default.
• W4387433013 hasConceptScore W4387433013C89423630 @default.
• W4387433013 hasConceptScore W4387433013C98274493 @default.
• W4387433013 hasIssue "340-341" @default.
• W4387433013 hasLocation W43874330131 @default.
• W4387433013 hasOpenAccess W4387433013 @default.
• W4387433013 hasPrimaryLocation W43874330131 @default.
• W4387433013 hasRelatedWork W13516814 @default.
• W4387433013 hasRelatedWork W2341617508 @default.
• W4387433013 hasRelatedWork W2351389548 @default.
• W4387433013 hasRelatedWork W2352788101 @default.
• W4387433013 hasRelatedWork W2367283725 @default.
• W4387433013 hasRelatedWork W2962035958 @default.
• W4387433013 hasRelatedWork W3030167655 @default.
• W4387433013 hasRelatedWork W102017176 @default.
• W4387433013 hasRelatedWork W2490746473 @default.
• W4387433013 hasRelatedWork W2549927882 @default.
• W4387433013 isParatext "false" @default.
• W4387433013 isRetracted "false" @default.
• W4387433013 workType "article" @default.